Fat metabolism during exercise in patients with mitochondrial disease

Archives of Neurology

Volumn 66, Issue 3, 2009, Pages 365-370

  Jeppesen, Tina Dysgaard ^a,b   Ørngreen, Mette Cathrine ^a   Van Hall, Gerrit ^a   Haller, Ronald G ^b,c   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Institute for Exercise and Environmental Medicine Dallas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FATTY ACID; GLUCOSE; LIPID; MITOCHONDRIAL DNA; PALMITIC ACID; STABLE ISOTOPE;

ADULT; ARTICLE; CALORIMETRY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; FATTY ACID BLOOD LEVEL; FEMALE; GLYCOLYSIS; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID OXIDATION; MALE; METABOLITE; MYOPATHY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESPIRATORY CHAIN; SKELETAL MUSCLE;

ADULT; CARBOHYDRATE METABOLISM; CASE-CONTROL STUDIES; ELECTRON TRANSPORT; EPINEPHRINE; EXERCISE; FATTY ACIDS; FEMALE; GLUCOSE; HORMONES; HUMANS; INSULIN; LIPID METABOLISM; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; NOREPINEPHRINE; OXYGEN CONSUMPTION; PALMITIC ACID;

EID: 62449204564     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.24     Document Type: Article

References (39)

1. Jeppesen TD, Schwartz M, Olsen DB, Vissing J. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. Ann Neurol. 2003;54(1):86-92.
2. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch Neurol. 2006;63(12):1701-1706.
3. Frederiksen AL, Andersen PH, Kyvik KU, Jeppesen TD, Vissing J, Schwartz M. Tissue specific distribution of the 3243 A>G mtDNA mutation. J Med Genet. 2006;43(8):671-677.
4. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF: the relationship between mutation load and clinical phenotypes. Brain. 1997;120(pt 10):1713-1721.
5. Berio A, Piazzi A. Improvement of Kearns-Sayre syndrome with controlled carbohydrate intake and coenzyme Q10 therapy. Ophthalmologica. 1994;208(6):342-343.
6. Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Ann Neurol. 2001;49(5):672-676.
7. Taivassalo T, Matthews PM, De Stefano N, et al. Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency. Neurology. 1996;47(2):529-534.
8. Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci. 1993;118(2):181-187.
9. Tanaka J, Nagai T, Arai H, et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev. 1997;19(4):262-267.
10. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212-218.
11. de Meer K, Roef MJ, de Klerk JB, Bakker HD, Smit GP, Poll-The BT. Increasing fat in the diet does not improve muscle performance in patients with mitochondrial myopathy due to complex I deficiency. J Inherit Metab Dis. 2005;28(1):95-98.
12. Ørngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61(4):559-561.
13. Ørngreen MC, Norgaard MG, van Engelen BG, Vistisen B, Vissing J. Effects of IV glucose and oral medium-chain triglyceride in patients with VLCAD deficiency. Neurology. 2007;69(3):313-315.
14. Haller RG, Vissing J. Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms. Arch Neurol. 2002;59(9):1395-1402.
15. Haller RG, Vissing J. Functional evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. New York, NY: McGraw-Hill Inc; 2004:665-679.
16. Anitori R, Manning K, Quan F, et al. Contrasting phenotypes in three patients with novel mutations in mitochondrial tRNA genes. Mol Genet Metab. 2005;84(2):176-188.
17. Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med. 2002;347(8):576-580.
18. Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism. 1981;30(9):936-940.
19. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92-98.
20. 13C-labelled substrate oxidation at whole-body and muscle level. Proc Nutr Soc. 1999;58(4):979-986.
21. Van Hall G, Bülow J, Sacchetti M, Al Mulla N, Lyngso D, Simonsen L. Regional fat metabolism in human splanchnic and adipose tissues: the effect of exercise. J Physiol. 2002;543(pt 3):1033-1046.
22. Vissing J, Vissing SF, MacLean DA, Saltin B, Quistorff B, Haller RG. Sympathetic activation in exercise is not dependent on muscle acidosis: direct evidence from studies in metabolic myopathies. J Clin Invest. 1998;101(8):1654-1660.
23. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959;82:420-430.
24. Wolfe RR. Radioactive and Stable Isotopes Tracers in Biomedicine: Principles and Practice of Kinetics Analysis. New York, NY: Wiley-Liss; 1992.
25. Péronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J Sport Sci. 1991;16(1):23-29.
26. van Loon LJ, Koopman R, Schrauwen P, Stegen J, Wagenmakers AJ. The use of the [1,2-13C]acetate recovery factor in metabolic research. Eur J Appl Physiol. 2003;89(3-4):377-383.
27. Ørngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology. 2002;59(7):1046-1051.
28. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med. 2003;349(26):2503-2509.
29. Ørngreen MC, Norgaard MG, Sacchetti M, van Engelen BG, Vissing J. Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Ann Neurol. 2004;56(2):279-283.
30. Nielsen JN, Wojtaszewski JF, Haller RG, et al. Role of 5′AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. J Physiol. 2002;541(pt 3):979-989.
31. Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry. 2008;79(12):1359-1363.
32. Roef MJ, de Meer K, Reijngoud DJ, et al. Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. Am J Clin Nutr. 2002;75(2):237-244.
33. Robertshaw HA, Raha S, Kaczor JJ, Tarnopolsky MA. Increased PFK activity and GLUT4 protein content in McArdle's disease. Muscle Nerve. 2008;37(4):431-437.
34. van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH, Wagenmakers AJ. The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol. 2001;536(pt 1):295-304.
35. Hepple RT, Liu PP, Plyley MJ, Goodman JM. Oxygen uptake kinetics during exercise in chronic heart failure: influence of peripheral vascular reserve. Clin Sci (Lond). 1999;97(5):569-577.
36. Lewis SF, Haller RG. The pathophysiology of McArdle's disease: clues to regulation in exercise and fatigue. J Appl Physiol. 1986;61(2):391-401.
37. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain. 2003;126(pt 2):413-423.
38. Galbo H. Integrated endocrine responses and exercise. In: Groot LJ, ed. Endocrinology. Philadelphia, PA: WB Saunders Co; 1995.
39. Becker R, Laube H, Linn T, Damian MS. Insulin resistance in patients with the mitochondrial tRNA(Leu(UUR)) gene mutation at position 3243. Exp Clin Endocrinol Diabetes. 2002;110(6):291-297.